CHMP grants positive opinion to dabrafenib and trametinib for BRAF positive NSCLC

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of dabrafenib in combination with trametinib to treat patients with advanced or metastatic non-small...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lB6jMt
via IFTTT